Reports Q4 revenue $17.23M, consensus $15.67M. “We capped an exciting year for Kestra with a very strong finish to our fiscal 2025. This quarter’s financial results reflect accelerating demand for our best-in-class cardiac recovery system as we continue to benefit from heightened prescriber awareness and the overwhelmingly positive experience patients are having with the ASSURE system,” said Brian Webster, president and CEO. “In addition to our commercial execution, we are encouraged by the meaningful improvement in our gross margin, a result of the attractive unit economics and positive leverage inherent in our business model.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMTS:
- KMTS Earnings this Week: How Will it Perform?
- Kestra Medical announces inclusion in Russell 2000, Russell 3000 Indexes
- Kestra Medical Appoints Conor Hanley to Board
- Kestra Medical appoints Conor Hanley to board of directors
- Optimistic Buy Rating for Kestra Medical Technologies Ltd. Driven by Strategic Expansion and Promising Financial Outlook